Table 1.
Clinical characteristics for all patients.
| Characteristics | Total cohort (n=146) (%) |
Immunotherapy | P value | |
|---|---|---|---|---|
| Without (n=66) (%) | With (n=80) (%) | |||
| Gender | 0.080 | |||
| Male | 78 (53.4) | 30 (45.5) | 48 (60.0) | |
| Female | 68 (46.6) | 36 (54.5) | 32 (40.0) | |
| Age(y) | 0.898 | |||
| <65 | 81 (55.5) | 37 (56.1) | 44 (55.0) | |
| ≥65 | 65 (44.5) | 29 (43.9) | 36 (45.0) | |
| Smoking History | 0.091 | |||
| Never-smoker | 84 (57.5) | 43 (65.2) | 41 (51.2) | |
| Former/current smoker | 62 (42.5) | 23 (34.8) | 39 (48.8) | |
| TNM stage | 0.215 | |||
| III | 13 (8.9) | 8 (12.1) | 5 (6.3) | |
| IV | 133 (91.1) | 58 (87.9) | 75 (93.7) | |
| Histology | 0.196 | |||
| Squamous | 2 (1.4) | 0 (0.0) | 2 (2.5) | |
| Adenocarcinoma | 144 (98.6) | 66 (100.0) | 78 (97.5) | |
| ECOG-PS | 0.472 | |||
| 0-1 | 136 (93.2) | 63 (95.5) | 73 (91.2) | |
| 2 | 10 (6.8) | 3 (4.5) | 7 (8.8) | |
| EGFR mutation type | 0.298 | |||
| 19del | 59 (40.4) | 31 (47.0) | 28 (35.0) | |
| 21L858R | 75 (51.4) | 31 (47.0) | 44 (55.0) | |
| Otders | 12 (8.2) | 4 (6.0) | 8 (10.0) | |
| Primary brain metastasis | 0.210 | |||
| Yes | 43 (29.5) | 16 (19.4) | 27 (23.6) | |
| No | 103 (70.5) | 50 (46.6) | 53 (56.4) | |
| Primary liver metastasis | 0.517 | |||
| Yes | 11 (7.5) | 6 (9.1) | 5 (6.3) | |
| No | 135 (92.5) | 60 (90.9) | 75 (93.7) | |
| EGFR-TKI | 0.358 | |||
| Gefitinib | 51 (34.9) | 21 (31.9) | 30 (37.5) | |
| Icotinib | 53 (36.3) | 22 (33.3) | 31 (38.8) | |
| Erlotinib | 7 (4.8) | 5 (7.6) | 2 (2.5) | |
| Afatinib | 10 (6.8) | 4 (6.1) | 6 (7.5) | |
| Osimertinib | 23 (15.8) | 13 (19.6) | 10 (12.5) | |
| Dacomitinib | 2 (1.4) | 1 (1.5) | 1 (1.2) | |